This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novo Nordisk, Dr. Reddy's emerge with partial wins in India's semaglutide patent suit

By Freny Patel ( December 4, 2025, 00:43 GMT | Insight) -- Dr. Reddy’s won permission to export semaglutide after an Indian court found that the domestic pharma company had raised a credible challenge to Novo Nordisk’s patent. However, the Delhi High Court barred domestic sales citing Dr Reddy’s “procedural mala fide,” or improper use of procedures.Novo Nordisk suffered a setback after an Indian court ruled that the domestic pharmaceutical major, Dr. Reddy’s Laboratories, had raised a credible prima facie challenge to its patent on semaglutide, the active ingredient in Ozempic....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login